Ainolsyakira Mohd Rodhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ainolsyakira Mohd Rodhi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Pei-Gee Yap
Analytical Biochemistry Research Centre (ABrC), Universiti Sains Malaysia, Penang, Malaysia
3 shared publications - Chee-Yuen Gan
Analytical Biochemistry Research Centre (ABrC), Universiti Sains Malaysia, George Town, Malaysia
2 shared publications - Muhammad Hakimin Shafie
Analytical Biochemistry Research Centre (ABrC), University Innovation Incubator (I(2)U), sains@usm Campus, Universiti Sains Malaysia, Lebuh Bukit Jambul, 11900 Bayan Lepas, Penang, Malaysia
2 shared publications - Ashfaq Ahmad
Department of Pharmacy Practice, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin 39524, Saudi Arabia
1 shared publication Bahruddin Saad
1 shared publicationChee‐Yuen Gan
Analytical Biochemistry Research Centre (ABrC), University Innovation Incubator Building, SAINS@USM Campus, Universiti Sains Malaysia Bayan Lepas Penang Malaysia
1 shared publication
Latest Publications
- 8 November 2025
- Published by Wiley in Peptide Science
- Vol. 117 (6)
Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which is responsible for the COVID‐19 pandemic, enters host cells by binding its spike protein to the angiotensin‐converting enzyme 2 (ACE) receptor on the surface of lung endothelial cells. ACE inhibitors, which were used to manage hypertension, have shown potential to interfere with this viral entry mechanism. This study investigates the dual inhibitory potential of ACE inhibitory peptides against furin, an essential enzyme for the activation of the SARS‐CoV‐2 spike protein. A molecular docking study was performed to identify key interacting amino acid residues at the N‐ and C‐termini that stabilize peptide–furin interactions. Key residues, including ARG, LYS, ALA, and VAL, along with the hydrophobic amino acids PRO, GLY, and LEU, play significant roles in stabilizing these interactions via hydrophobic forces. These residues enhance peptide–enzyme affinity by contributing structural rigidity and flexibility, optimizing binding orientation. The analysis revealed that most ACE inhibitory peptides engage in noncompetitive inhibition by binding to an allosteric site on furin, composed of key residues, such as GLU271, GLY307, SER311, TYR313, LYS449, GLN488, ARG490, ASP530, and ALA532. In vitro and in vivo studies are necessary to further evaluate the therapeutic safety and efficacy of these peptides, paving the way for innovative treatment strategies against COVID‐19.
- 8 November 2025
- Published by Wiley in Peptide Science
- Vol. 117 (6)
Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which is responsible for the COVID‐19 pandemic, enters host cells by binding its spike protein to the angiotensin‐converting enzyme 2 (ACE) receptor on the surface of lung endothelial cells. ACE inhibitors, which were used to manage hypertension, have shown potential to interfere with this viral entry mechanism. This study investigates the dual inhibitory potential of ACE inhibitory peptides against furin, an essential enzyme for the activation of the SARS‐CoV‐2 spike protein. A molecular docking study was performed to identify key interacting amino acid residues at the N‐ and C‐termini that stabilize peptide–furin interactions. Key residues, including ARG, LYS, ALA, and VAL, along with the hydrophobic amino acids PRO, GLY, and LEU, play significant roles in stabilizing these interactions via hydrophobic forces. These residues enhance peptide–enzyme affinity by contributing structural rigidity and flexibility, optimizing binding orientation. The analysis revealed that most ACE inhibitory peptides engage in noncompetitive inhibition by binding to an allosteric site on furin, composed of key residues, such as GLU271, GLY307, SER311, TYR313, LYS449, GLN488, ARG490, ASP530, and ALA532. In vitro and in vivo studies are necessary to further evaluate the therapeutic safety and efficacy of these peptides, paving the way for innovative treatment strategies against COVID‐19.
- 9 February 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1305
Unveiling α-Amylase Inhibition: A Bioinformatics Perspective on Peptide Properties and Amino Acid Contributions
- 9 February 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1305
Unveiling α-Amylase Inhibition: A Bioinformatics Perspective on Peptide Properties and Amino Acid Contributions
- Open Access
- 1 May 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (3) , em470
A comprehensive review on the pancreatic lipase inhibitory peptides: A future anti-obesity strategy
Dysregulation of lipid homeostasis contributes to obesity and can directly lead to several critical public health concerns globally. This paper aimed to present a brief review of related properties and the use of pancreatic lipase inhibitors as the future weight loss drug discovery and development procured from a wide range of natural sources. A total of 176 pancreatic lipase inhibitory peptides were identified from recent publications and peptide databases. These peptides were classified into three categories according to their peptide length and further analyzed using bioinformatic approaches to identify their structural activity relationship. Molecular docking analyses were conducted for each amino acid at the terminal position of the peptides to predict the binding affinity between peptide-enzyme protein complexes based on intermolecular contact interactions. Overall, the observations revealed the features of the inhibitory peptides and their inhibitory mechanisms and interactions. These findings strived to benefit scientists whose research may be relevant to anti-obesity drug development and/or discovery thereby support effective translation of preclinical research for humans’ health being.
- 1 May 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (3) , em470
Open AccessA comprehensive review on the pancreatic lipase inhibitory peptides: A future anti-obesity strategy
Dysregulation of lipid homeostasis contributes to obesity and can directly lead to several critical public health concerns globally. This paper aimed to present a brief review of related properties and the use of pancreatic lipase inhibitors as the future weight loss drug discovery and development procured from a wide range of natural sources. A total of 176 pancreatic lipase inhibitory peptides were identified from recent publications and peptide databases. These peptides were classified into three categories according to their peptide length and further analyzed using bioinformatic approaches to identify their structural activity relationship. Molecular docking analyses were conducted for each amino acid at the terminal position of the peptides to predict the binding affinity between peptide-enzyme protein complexes based on intermolecular contact interactions. Overall, the observations revealed the features of the inhibitory peptides and their inhibitory mechanisms and interactions. These findings strived to benefit scientists whose research may be relevant to anti-obesity drug development and/or discovery thereby support effective translation of preclinical research for humans’ health being.
- 1 April 2014
- Published by Elsevier in Food Control
- Vol. 38, 142-149
High performance liquid chromatography method for the determination of patulin and 5-hydroxymethylfurfural in fruit juices marketed in Malaysia
- 1 April 2014
- Published by Elsevier in Food Control
- Vol. 38, 142-149
High performance liquid chromatography method for the determination of patulin and 5-hydroxymethylfurfural in fruit juices marketed in Malaysia